- Home
- RIGL vs ADSE Comparison
RIGL vs ADSE Comparison
Compare RIGL & ADSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | ADSE |
|---|---|---|
| Founded | 1996 | 1980 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.8M | 900.0M |
| IPO Year | 2000 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RIGL | ADSE |
|---|---|---|
| Price | $51.03 | $9.79 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $63.00 | N/A |
| AVG Volume (30 Days) | ★ 187.5K | 38.4K |
| Earning Date | 11-05-2026 | 10-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | $3.89 | $1,305.94 |
| Revenue Next Year | $21.95 | N/A |
| P/E Ratio | $38.83 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $8.51 |
| 52 Week High | $52.24 | $13.50 |
Technical Indicators
Market Signals| Indicator | RIGL | ADSE |
|---|---|---|
| Relative Strength Index (RSI) | 61.97 | 46.75 |
| Support Level | $44.83 | $9.81 |
| Resistance Level | N/A | $12.17 |
| Average True Range (ATR) | 1.53 | 0.68 |
| MACD | 0.30 | 0.07 |
| Stochastic Oscillator | 75.79 | 75.28 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.